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Background. Intrapartum antibiotic chemoprophylaxis (IAP) prevents most early-onset group B streptococcal (GBS) disease. 
However, there is no description of how IAP is used around the world. This article is the sixth in a series estimating the burden of 
GBS disease. Here we aimed to review GBS screening policies and IAP implementation worldwide.
Methods. We identified data through (1) systematic literature reviews (PubMed/Medline, Embase, Literature in the Health 
Sciences in Latin America and the Caribbean [LILACS], World Health Organization library database [WHOLIS], and Scopus) and 
unpublished data from professional societies and (2) an online survey and searches of policies from medical societies and profession-
als. We included data on whether an IAP policy was in use, and if so whether it was based on microbiological or clinical risk factors 
and how these were applied, as well as the estimated coverage (percentage of women receiving IAP where indicated).
Results. We received policy information from 95 of 195 (49%) countries. Of these, 60 of 95 (63%) had an IAP policy; 35 of 
60 (58%) used microbiological screening, 25 of 60 (42%) used clinical risk factors. Two of 15 (13%) low-income, 4 of 16 (25%) 
lower-middle–income, 14 of 20 (70%) upper-middle–income, and 40 of 44 (91%) high-income countries had any IAP policy. The 
remaining 35 of 95 (37%) had no national policy (25/33 from low-income and lower-middle–income countries). Coverage varied 
considerably; for microbiological screening, median coverage was 80% (range, 20%–95%); for clinical risk factor–based screening, 
coverage was 29% (range, 10%–50%). Although there were differences in the microbiological screening methods employed, the 
individual clinical risk factors used were similar.
Conclusions. There is considerable heterogeneity in IAP screening policies and coverage worldwide. Alternative global strate-
gies, such as maternal vaccination, are needed to enhance the scope of global prevention of GBS disease.
Keywords. group B Streptococcus; intrapartum antibiotic chemoprophylaxis. 
Group B Streptococcus (GBS; Streptococcus agalactiae) is a lead-
ing cause of early-onset disease in infants (EOGBS), defined as 
disease occurring on days 0–6 after birth [1]. Colonization of 
the maternal genitourinary or gastrointestinal tract [2] is a pre-
requisite for EOGBS disease [3, 4], with vertical transmission 
of GBS to babies occurring at or just before birth. The admin-
istration of intrapartum antibiotics aims to prevent EOGBS 
and is traditionally targeted based on known GBS coloniza-
tion and/or the presence of peripartum clinical risk factors [4]. 
The potential mechanisms for prevention of EOGBS include 
reduction or suppression of maternal vaginal GBS colonization 
and thereby reduction of vertical transmission [5]. In addition, 
intrapartum antibiotic chemoprophylaxis (IAP) may allow the 
early treatment of GBS chorioamnionitis or fetal infection [6].
IAP has been recommended in the United States by the 
Centers for Disease Control and Prevention, American College of 
Obstetrics and Gynecologists, American Academy of Pediatrics, 
American Society for Microbiology, and American College of 
Nurse-Midwives since the early 1990s, with the first consensus 
policy in 1996 [7]. Initially the United States recommended both 
risk-based and microbiological screening. However, a large mul-
ticenter cohort study in 2002 [8] found microbiological screening 
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to be superior in this setting. Subsequently, policy was changed to 
recommend microbiologic screening (using a rectovaginal swab) 
for GBS colonization at 35–37 weeks’ gestation or among women 
with threatened preterm delivery and unknown colonization 
status, and administration of high-dose intravenous benzylpen-
icillin or ampicillin in labor among those GBS colonized [4, 9]. 
Additionally, women with GBS bacteriuria or a previous infant 
with GBS disease as well as women with unknown colonization 
status and intrapartum risk factors such as prolonged rupture of 
membranes or maternal fever, are offered IAP in labor. A signif-
icant reduction in the incidence of EOGBS has been reported 
since the introduction of IAP policies [4, 9]; EOGBS disease in 
the United States declined from 1.7 per 1000 live births in the 
1990s to 0.21 per 1000 live births in 2015 [10]. However, a recent 
Cochrane review found that although IAP may reduce the inci-
dence of EOGBS, it did not result in a significant reduction in the 
mortality associated with EOGBS [11]. The review was critical of 
the quality of the studies included and considered there to be a 
high risk of bias in their methodology and execution.
Other countries such as the United Kingdom and the 
Netherlands have introduced IAP polices based on the pres-
ence of clinical risk factors. Risk factors used include preterm 
labor (<37 weeks) or premature or prolonged preterm rupture 
of membranes, GBS bacteriuria, previous infant with GBS dis-
ease, and maternal pyrexia (temperature >38°C) [12–14]. The 
use of clinical risk factor–based IAP strategies rather than 
microbiological screening is based on the assessment that the 
introduction of routine microbiological screening may not be 
cost-effective and that clinical risk factor–based IAP may result 
in fewer women being exposed to the potential risks associ-
ated with widespread antibiotic use [14, 15]. There is currently 
no international consensus as to whether IAP is best achieved 
through microbiological screening or based on the presence of 
clinical risk factors. There is evidence from the United States 
that the incidence of EOGBS has declined since the introduc-
tion of clinical screening strategies, although a larger propor-
tion of women are treated with IAP using clinical as opposed to 
risk-based strategies [8]. Any consensus regarding IAP strate-
gies should take potentially opposing points into consideration.
This review is part of a supplement estimating the burden 
of GBS disease in pregnant women, stillbirths, and infants, 
an important topic that has important implications for public 
health policy as well as for future vaccine development [16]. The 
supplement includes systematic reviews and meta-analyses on 
GBS colonization, and adverse outcomes associated with GBS 
around birth [1, 2, 17–22], which form input parameters to a 
compartmental model (Figure 1) [23]. These are reported indi-
vidually and according to international guidelines [24, 25].
The objectives of this review are:
1. To undertake a comprehensive and systematic literature 
review, and a survey of national obstetric and gynecological 
societies, to assess the presence of IAP policies worldwide, 
the strategies and methods used, and where possible, cover-
age or the status of implementation;
2. To assess these data for input into estimating the global bur-
den of GBS in pregnancy, stillbirth, and infants;
3. To summarize the data gaps to inform future strategies for 
the prevention of GBS disease, including maternal vaccina-
tion, globally.
METHODS
This article is part of a protocol entitled “Systematic estimates 
of the global burden of Group B Streptococcus in pregnant 
women, stillbirths and infants,” which was submitted for ethical 
approval to the London School of Hygiene & Tropical Medicine 
(reference number 11966) and approved on 30 November 2016.
Data Searches and Inputs
We identified data through 2 sources: (1) systematic review of 
the published literature and (2) reviews of online policies and 
an online survey submitted to clinicians, researchers, and rele-
vant professionals worldwide.
Literature Searches
We undertook systematic literature searches of Medline, 
Embase, Literature in the Health Sciences in Latin America 
and the Caribbean (LILACS), Scopus, and the World Health 
Organization library database (WHOLIS). The literature search 
was updated on 20 January 2017. We used the search terms 
“antibiotics,” “intrapartum,” “group B Streptococcus,” and “col-
onization” with no date or language restrictions (full search 
terms are listed in Supplementary Table  1). We additionally 
searched the China Academic Journals Full-Text Database 
(with a time restriction of 3 years), and a Russian online data-
base (Cyberleninka) with no date restrictions, as these data are 
often not present on classical database searches. We abstracted 
the data from articles in foreign languages alongside translators 
where available and used automatic translation if native speakers 
were unavailable.
Reviews of Online Policies and an Online Survey
We searched for online policies of all 130 countries listed on 
the International Federation of Gynecology and Obstetrics 
(FIGO) website [26] to identify the latest policies. In addition, 
we designed an online survey (Supplementary Materials 2) 
and approached the World Health Organization (WHO) Safer 
Childbirth Group, FIGO, the Royal College of Obstetricians 
and Gynaecologists, and the European Society for Paediatric 
Infectious Diseases to disseminate to their members.
Inclusion and Exclusion Criteria
Two authors (K. L. D. and K. T.) independently abstracted data 
onto standard Excel data entry forms. Policies were reviewed 
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according to the inclusion and exclusion criteria below. For 
any discrepancies, a third researcher (M. O.) was consulted. 
We included any document detailing IAP policy and strat-
egy: microbiological screening (including sample site of swab 
and gestation of screening), clinical risk factors, the type and 
route of antibiotic administered, and an estimate of IAP cover-
age within that country. We excluded any policy that had been 
revoked or was under review (Supplementary Table 2).
To ensure results were current, we selected the latest available 
policy from each country. The hierarchy of policy documents, 
based on their likely accuracy, was as follows: (1) national pol-
icy document available from relevant national association; (2) 
national policy available from published literature; (3) national 
policy available from survey participant.
We categorized countries into 4 groups: (1) no IAP policy or 
low implementation (0%); (2) microbiological screening pol-
icy with limited implementation (defined as <50% of eligible 
women receiving IAP); (3) clinical risk factor–based screening 
with high implementation (defined as >50% of eligible women 
receiving IAP); (4) universal microbiological screening policy 
with high implementation (defined as ≥50% of eligible women 
receiving IAP). We did an ecological analysis comparing coun-
try IAP policy by category with EOGBS disease incidence as a 
scatterplot.
RESULTS
Study Selection
We identified 853 articles, of which we retained 60 after title and 
abstract screening for review of full texts (Figure 2). We excluded 
a further 15 articles after full-text review as these either presented 
duplicate data (n = 7), did not have policy data in the main text 
(n = 3), or did not make full text available (n = 5), leaving 45 arti-
cles for inclusion in the analysis. Of these, details of policy were 
already available from 30 national policy documents, leaving 15 
articles containing additional policy information.
Using the international list of obstetric and gynecological 
societies listed on the FIGO website, we identified online policy 
documents from 42 countries and received responses that there 
was no national policy from 19 countries through FIGO. Of the 
remaining 71 countries, either there was no society website or 
no working email address, or the contacts did not reply to the 
FIGO email, despite receiving a read-receipt.
We received responses from 265 participants to our survey 
(Figure 2). We excluded 238 due to duplicate entries with iden-
tical responses from participants in the same country (n = 142), 
incomplete responses (n  =  32), or because policy documents 
had already been received from the country’s obstetric associa-
tion and survey responses matched the country policy (n = 72), 
leaving 19 unique survey responses. Details are reported in 
Figure 1. Intrapartum antibiotic chemoprophylaxis in disease schema for group B streptococcal (GBS) disease, as described by Lawn et al [16].
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Supplementary Table 3. The final dataset included policies from 
95 countries (FIGO = 61; original articles = 15; survey = 19)
Intrapartum Antibiotic Chemoprophylaxis Policy and Implementation 
Strategies
Sixty of 95 countries had a national IAP policy. The strategies 
used varied: 25 of 60 (42%) used a risk factor–based approach 
and 35 of 60 (58%) used both microbiological screening and 
risk factor approaches. Thirty-five of 95 (37%) countries had 
no national policy. Within these, there were reports of policies 
from hospitals or localities in 9 countries. Of these, 5 of 35 
used rapid screening at point of labor only and 4 of 35 used 
risk factor approaches. Figure 3 shows countries where IAP 
policies were identified and Figure 4 shows IAP policy type 
globally.
Intrapartum Antibiotic Chemoprophylaxis Policy by Region and 
Income Status
We received responses concerning IAP policy from all regions. 
All developed region countries had an IAP policy (34/34). Other 
regions varied with the majority of countries in sub-Saharan Africa 
(3/20) and East Asia (1/3) reporting no IAP policy (Table 1).
Figure 2. Flowchart of intrapartum antibiotic chemoprophylaxis policy data identified through systematic searches and other means. Abbreviations: FIGO, International 
Federation of Gynecology and Obstetrics; GBS, group B Streptococcus; IAP, intrapartum antibiotic chemoprophylaxis; PRISMA, Preferred Reporting Items for Systematic 
Reviews and Meta-analyses.
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The majority of countries reporting no policy came from low 
and lower-middle–income countries (25/33 [76%]). Two coun-
tries had limited IAP strategies, reported as risk-based screen-
ing in hospitals run by the charitable organization Médecins 
sans Frontières. Of countries reporting any IAP policy, 4 of 
16 (25%) were from lower-middle–income countries (all risk-
based screening policies). In upper-middle–income countries, 
8 of 20 reported microbiological policy and 6 of 20 risk-based 
policy, whereas in high-income countries, 24 of 44 had micro-
biological and 16 of 44 risk-based policies. (Supplementary 
Table 3).
For countries with an IAP policy, implementation var-
ied both within and between countries. Implementation was 
more frequently reported as high in countries with microbio-
logical screening (median, 80% [range, 20%–95%]) compared 
to countries with clinical risk factor–based approaches (29% 
[range, 10%–50%]). Policy documents estimating implementa-
tion varied from estimates based on clinician reporting, espe-
cially in countries using clinical risk factor–based approaches, 
where clinician reporting was lower than that reported in policy 
documents.
Microbiological Screening for Intrapartum Antibiotic Chemoprophylaxis 
Administration
In 35 countries reporting microbiological screening (30 national 
screening, 5 hospital-level screening), women were usually 
screened at 35–37 weeks’ gestation. Two countries (Bulgaria and 
Japan) offered additional microbiological screening at 20 weeks’ 
gestation. In 5 countries (Poland, Bangladesh, Iran, Thailand, 
and Trinidad and Tobago), individual hospitals offered point-
of-care screening using polymerase chain reaction when women 
presented in labor, in addition to screening at 35–37 weeks’ ges-
tation. The estimated coverage of these guidelines varied greatly 
and ranged from 20% in Brazil to 89% in the United States 
and Belgium (median, 80%). Where microbiological screening 
methods were reported (n  =  35), 21 reported sampling both 
the rectum and vagina either with separate (n = 2) or combined 
(n = 19) swabs, and 14 used only vaginal swabs.
Figure 3. Distribution of national policies for maternal group B Streptococcus screening and administration of intrapartum antibiotics. Borders of countries/territories in 
map do not imply any political statement.
Figure 4. Distribution of policies for maternal group B Streptococcus screening by type of policy. Borders of countries/territories in map do not imply any political statement.
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Clinical Risk Factors for Intrapartum Antibiotic Chemoprophylaxis 
Administration
Twenty-five countries reported IAP based on clinical risk fac-
tors (14 national, 11 regional/hospital). There was little var-
iation in risk factors used to determine the need for IAP. All 
recommended IAP use if a previous infant had GBS disease; the 
majority (23/25) also recommended IAP for preterm prolonged 
rupture of membranes, premature rupture of membranes >18 
hours (PROM), or maternal GBS bacteriuria. The clinical risk 
factors are listed in Table 2.
Two middle-income countries reported IAP administra-
tion based on clinical risk factors (Kenya and South Africa). 
However, responses from the online survey suggest that cover-
age of this policy in these countries was low.
Clinician Responses to Survey Compared to National Policy
There was considerable variation in the survey responses 
between countries concerning the question “Does your coun-
try have a national policy for intrapartum antibiotics to prevent 
neonatal group B streptococcal disease?” In countries with risk-
based screening policies, one-third of respondents answered 
“no,” although their obstetric societies have published national 
guidance. There was no discrepancy in countries reporting 
microbiological screening approaches.
Antibiotics Administered
The majority of policies (50/60) recommended intravenous 
penicillin–based antibiotics (38/50 penicillin, 12/50 ampicillin) 
and clindamycin in cases of confirmed penicillin allergy. Six 
countries recommended a cephalosporin rather than penicillin 
and 4 countries in South America and 2 in Asia recommended 
additional vancomycin because of concerns about a theoretical 
risk of developing antibiotic resistance in their populations in 
patients with penicillin allergy.
Effect of Screening Policy on EOGBS Incidence in Countries Reporting 
Both National Policy and National EOGBS Incidence
EOGBS incidence data were available for 32 countries: 12 
reporting a microbiological and risk-based strategy, 15 report-
ing a clinical risk factor strategy, and 5 reporting no national 
policy. The results are presented in Figure 5. Broadly, EOGBS 
incidence was lower in countries with a microbiological and 
clinical risk–based policy [1].
DISCUSSION
This review of IAP policies to prevent EOGBS disease repre-
sents the first systematic review and survey of GBS screening 
policies to date, with data from 95 countries of the 195 United 
Nations member states. It clearly demonstrates that IAP policy, 
strategy, and implementation are heterogeneous and different 
disease burden estimates and healthcare systems have led to a 
range of IAP approaches. This may imply that opportunities for 
prevention of EOGBS are being missed in some settings.
Whereas the WHO advocates screening for GBS during 
pregnancy, it also recognizes that screening for all pregnant 
women—especially in settings with known low maternal col-
onization prevalence, low-resource countries, and/or countries 
where provision of care is limited—is difficult to implement. The 
WHO therefore recommends that IAP should be implemented 
Table  2. Clinical Risk Factors Used as a Basis for Antibiotic 
Administration to Reduce Group B Streptococcal Disease at Delivery
Risk Factor No. of Countries Reporting (n = 25)
Previous infant with GBS 25
GBS in urine 23
PROM >18 h 23
PROM >24 h 2
Premature labor 23
Maternal fever 20
Chorioamnionitis 2
Abbreviations: GBS, group B Streptococcus; PROM, premature rupture of membranes.
Figure 5. Scatterplot of early-onset disease incidence by national intrapartum 
antibiotic chemoprophylaxis (IAP) policy type.
Table 1. Intrapartum Antibiotic Chemoprophylaxis by Region and Income 
Status
Region Responses IAP Policy Microbiological
Risk Factor 
Based No Policy
Developed 
regions
34 34 22 12 0
East Asia 3 1 0 1 2
Latin 
America
12 9 7 2 3
North Africa 3 1 0 1 2
Southeast 
Asia
7 5 3 2 4
South Asia 7 4 1 2 3
Sub-Saharan 
Africa
20 3 0 2 17
West Asia 9 5 2 3 4
Abbreviation: IAP, intrapartum antibiotic chemoprophylaxis.
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within the context of local policy and guidance on screening 
for GBS colonization [27]. In our study, low- and middle-in-
come countries more frequently reported having no IAP policy 
as compared to high-income countries. There were exceptions 
to this; for example, both Kenya and South Africa had national 
IAP policies, although the survey suggested that implementa-
tion and coverage were low. In countries where access to skilled 
care is limited, or where the majority of births occur at home 
(eg, in some low-income countries where up to 80% of births are 
at home), implementation of IAP will always pose a challenge.
Other concerns relate to the acceptability of screening by 
women in high-income countries, especially the use of vaginal 
and rectal swabs and increased interventions during pregnancy 
that will limit the implementation of any IAP strategy.
It is estimated that >40% of women in the United States now 
receive antibiotics in labor, either for the prevention of EOGBS 
disease or to prevent postpartum infections following cesar-
ean delivery [28]. Such widespread use of antibiotics in preg-
nancy has been raised as a concern, both in terms of potential 
impact on antimicrobial resistance and on possible long-term 
consequences in infants exposed in utero or around the time of 
birth. For example, an increase in infections due to Escherichia 
coli, especially in preterm infants, was demonstrated, follow-
ing widespread IAP use in the United States [29, 30]. However, 
despite almost 20 years of IAP use, there is no evidence for this 
in large epidemiological studies in the United States [31]. Other 
issues include maternal anaphylaxis to β-lactams [32]. More 
theoretical concerns include the effect of maternal antibiotic 
use on the maternal and infant gut and skin flora, on the neo-
natal microbiome, and on subsequent immunological priming 
[33]. Alterations in the neonatal intestinal microbiome have 
been associated with increased rates of allergy, asthma, and 
obesity [34]. This is an area that requires further investigation 
in countries that offer IAP.
A maternal GBS vaccine may be the ideal solution to help 
reduce the burden of neonatal GBS disease in all settings. 
Implementation of a vaccine is likely to be higher than suc-
cessful administration of IAP, especially in low- and middle-in-
come settings and will protect against at least 75% of EOGBS. 
However, in some high-income settings, it may be feasible to 
combine with IAP when vaccination might be unavailable or 
suboptimal [35].
Our study also provides important additional information 
on national policies through its searches outside of scientific 
literature. However, responses from individual clinicians may 
not necessarily be representative of the different levels of health-
care and of health facilities that exist within a country, and we 
acknowledge the limitations to this approach. In high-income 
contexts, countries using both microbiological and clinical risk 
factor–based approaches for IAP had low reported EOGBS inci-
dence [1]. We cannot assume causality, however, as this finding 
may reflect other differences in healthcare such as access to care. 
We were also unable to correlate reported EOGBS incidence 
with the introduction of IAP policy in all of these countries, 
as policy may have been put into place after EOGBS data were 
collected. The reliability of data on implementation coverage of 
policies are hard to verify, and we have therefore categorized 
them using very broad thresholds (< 50% or >50%). This is 
important in terms of understanding the burden of disease; the 
category influences the risk of EOGBS disease [2] at an indi-
vidual level, and is thus important in terms of a compartmental 
approach to modeling disease burden [16].
In conclusion, local, national, and international policies 
should be informed by the strongest evidence for the preven-
tion of EOGBS and might require tailored solutions to succeed. 
Future GBS vaccines may offer the best opportunity to prevent 
EOGBS in any setting, with better implementation than policies 
for IAP currently in use (Table 3).
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
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Notes
Author contributions. The concept of the estimates and the technical 
oversight of the series were led by J. E. L. and A. C. S. The reviews, analyses, 
and first draft of the manuscript were undertaken by K. L. D. with K. T., F. S., 
M. O., B. K., A. C. S., J. E. L., and P. T. H. Survey design was undertaken by K. 
L. D. and K. T. The GBS Estimates Expert Advisory Group (C. J. B., L. B., C. 
C., M. G. G., M. I., S. A. M., C. E. R., S. K. S., S. S., A. S.-t. M., J. V.) contributed 
to the conceptual process throughout, notably on the disease schema and 
data inputs. The IAP investigator group (Angela Ramoni, Rikke Bek Helmig, 
Kaarin Makikallio, Tengiz Asatinai, Menachem Fisher, Michael Feinstein, Oz 
Yuval, Matan Elami Suzin, Vered Eisenberg, Alberto Berardi, Indi Trehan, 
Table 3. Key Findings and Implications
What’s new about this?
• GBS is an important perinatal pathogen. IAP is the most widely practiced 
intervention for preventing early onset GBS, yet no worldwide data exists 
regarding national policies or levels of implementation. This is the first sys-
tematic review of IAP policies based on published data, online survey, and 
reviews of national policies.
What was the main finding?
• Data were identified on IAP policy for 95 countries (of 195 UN member 
states). Content on policy approach by country included microbiological 
screening and which antibiotics used.
How can the data be improved?
• There is no current means to routinely track GBS IAP policy at the national 
level, and it would be beneficial to include in the WHO annual Maternal 
Neonatal and Child Health policy survey. Data for implementation/cover-
age are even harder to identify; therefore, it is difficult to assess program 
status or effect.
What does it mean for policy and programs?
• Variable policies—and in some countries internal inconsistencies in report-
ing of policies, and likely even more variable implementation between 
and within countries. These data are relevant in considering maternal GBS 
vaccination—which may be more likely to reach the poorest at higher cov-
erage than IAP and also be easier to track in national policy.
Abbreviations: GBS, group B Streptococcus; IAP, intrapartum antibiotic chemoprophylaxis; 
UN, United Nations; WHO, World Health Organization.
Downloaded from https://academic.oup.com/cid/article-abstract/65/suppl_2/S143/4589585
by St George's University of London user
on 10 November 2017
S150 • CID 2017:65 (Suppl 2) • Le Doare et al
Georgia Leigh Macad, Miha Lucovnik, Claire Nkiruka Oluwalana, Pippa 
Letchworth, Martin Jagoutz-Herlinger, Francis Githae Muriithi, Kouther Issa 
Yassen, Gerard Visser, Johan Vos, and Sophie Cooper) input data for the anal-
yses. All the authors reviewed and gave input to the manuscript.
Acknowledgments. We thank Jane Plumb, Group B Strep Support, Dr 
Tejshri Shah, Médecins sans Frontières (MSF), and Anne Cugier, MSF, for 
helping with the dissemination of the survey; Claudia da Silva for admin-
istrative assistance; and Alegria Perez for coordinating author signatures.
GBS Intrapartum Antibiotic Investigator Group. Dr Angela Ramoni 
(Universitätsklinik, Innsbruck, Austria), Dr Rikke Bek Helmig (Department 
of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby, 
Denmark), Dr Kaarin Makikallio (Department of Obstetrics and 
Gynaecology, Turku University Hospital, Finland), Prof. Tengiz Asatiani 
(President of Georgian Obstetricians and Gynaecologists Association, State 
Medical University, Georgia), Dr Menachem Fisher (Bar-Ilan Iniversity, 
Faculty of Medicine, Zefat, Israel), Dr Michael Feinstein (Kaplan Hospital, 
Rechovot, Israel), Dr Yuval Oz (Israel), Dr Matan Elami Suzin (Hadassah 
Hebrew University Medical Centre, Jerusalem, Israel), Dr Vered Eisenberg 
(MHA Sheba Medical Centre, Tel Hashomer and Sacker Faculty of 
Medicine, Tel Aviv, Israel), Dr Alberto Berardi (Unit Unità Operativa di 
Terapia Intensiva Neonatale, Azienda Ospedaliero-Universitaria Policlinico, 
Modena, Italy), Dr. Indi Trehan (Partners In Health, Liberia, Washington 
University, St Louis, Missouri; University of Malawi), Mrs. Georgia Leigh 
Macad (CPM (Certified Professional Midwife) Director and Founder of 
Abundant Grace of God Maternity Center, Tabuk City, Kalinga Philippines), 
Assoc. Prof. Miha Lucovnik (Department of Perinatology, Division 
of Obstetrics and Gynaecology, University Medical Centre, Ljubljana, 
Slovenia), Dr Claire Nkiruka Oluwalana (MRC Unit, The Gambia), Dr. 
Pippa Letchworth (Chelsea and Westminster Hospital, London, UK), 
Dr. Martin Jagoutz-Herzlinger (practitioner, Austria), Dr. Francis Githae 
Muriithi (Centre for Maternal and Newborn Health, Liverpool School of 
Tropical Medicine, Liverpool, UK), Dr. Kouther Issa Yassen (Practitioner, 
Miassan, Iraq), Prof. Gerard Visser (President International Federation of 
Obstetrics and Gynaecology, Geneva, Switzerland), Ms. Sophie Cooper 
(Royal College of Obstetrics and Gynaecology, London, UK).
Disclaimer. The findings and conclusions in this article are those of the 
authors and do not necessarily represent the official position of any of the 
agencies or organizations listed.
Financial support. This supplement was supported by a grant to the 
London School of Hygiene & Tropical Medicine from the Bill & Melinda 
Gates Foundation (reference number OPP1131158).
Supplement sponsorship. This article appears as part of the supple-
ment “The Burden of Group B Streptococcus Worldwide for Pregnant 
Women, Stillbirths, and Children,” sponsored by the Bill & Melinda Gates 
Foundation and coordinated by the London School of Hygiene & Tropical 
Medicine.
Potential conflicts of interest. Many contributors to this supple-
ment have received funding for their research from foundations, espe-
cially the Bill & Melinda Gates Foundation, and several from Wellcome 
Trust, Medical Research Council UK, the Thrasher Foundation, the 
Meningitis Research Foundation, and one individual from the US 
National Institutes of Health. Members of the Expert Advisory Group 
received reimbursement for travel expenses to attend working meet-
ings related to this series. A. S.-t. M. works for the Bill & Melinda Gates 
Foundation. A.  B.  attended a Pfizer Advisory Board meeting in Paris, 
2015; received consultancy funding from Putnam Associates; received a 
consultancy fee from GSK for a conference interview; and collaborated 
in the Devani Project funded by the European Union. B. K. has partici-
pated in board meetings as scientific advisor for GSK and Pfizer on the 
subject of maternal immunization. C.  J. B.  has served as a member of 
the Presidential Advisory Committee for Seqirus Inc and of the CureVac 
Inc Scientific Advisory Committee, as well as undertaken consultancy 
work for Pfizer Inc. C. C. has received institutional compensation from 
Novartis for conducting GBS studies. P. T. H. has been a consultant to 
Novartis and Pfizer on GBS vaccines but received no funding for these 
activities. M. I. has undertaken sponsored research from Pfizer on pneu-
mococcal disease in adults and from Belpharma Eumedica (Belgium) 
on temocillin antimicrobial susceptibility in Enterobacteriaceae. K.  L. 
D. has received funding by the Bill & Melinda Gates Foundation to work 
on research on GBS serocorrelates of protection to inform vaccine tri-
als, and travel expenses from Pfizer to attend a meeting on an investiga-
tor-led project on GBS. S. A. M. has collaborated on GBS grants funded 
by GlaxoSmithKline and by Pfizer and received personal fees for being 
member of its advisory committee; he has also collaborated on a GBS 
grant funded by Minervax. All other authors report no potential conflicts 
of interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant 
to the content of the manuscript have been disclosed.
References
1. Madrid L, Seale AC, Kohli-Lynch M, et al. Infant group B streptococcal disease 
incidence and serotypes worldwide: systematic review and meta-analyses. Clin 
Infect Dis 2017; 65(suppl 2):S160–72.
2. Russell N, Seale AC, O’Sullivan C, et  al. Risk of early-onset neonatal group B 
streptococcal disease with maternal colonization worldwide: systematic review 
and meta-analyses. Clin Infect Dis 2017; 65(suppl 2):S152–9.
3. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of peri-
natal group B streptococcal disease: experience in the United States and implications 
for a potential group B streptococcal vaccine. Vaccine 2013; 31 (suppl 4):D20–6.
4. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center 
for Immunization and Respiratory Diseases, Centers for Disease Control and 
Prevention (CDC). Prevention of perinatal group B streptococcal disease—
revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1–36.
5. Baltimore RS. Consequences of prophylaxis for group B streptococcal infections 
of the neonate. Semin Perinatol 2007; 31:33–8.
6. Martinelli P, Sarno L, Maruotti GM, Paludetto R. Chorioamnionitis and prematu-
rity: a critical review. J Matern Fetal Neonatal Med 2012; 25(suppl 4):29–31.
7. ACOG Committee Opinion. Prevention of early-onset group B streptococcal disease 
in newborns. Number 173—June 1996. Committee on Obstetric Practice. American 
College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 1996; 54: 197–205.
8. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group 
B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 
2002; 51:1–22.
9. Colbourn T, Gilbert R. An overview of the natural history of early onset group B 
streptococcal disease in the UK. Early Hum Dev 2007; 83:149–56.
10. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance 
(ABCs) Report. Emerging Infections Program Network Group B Streptococcus, 
2015. Atlanta, 2015.
11. Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal group B strep-
tococcal colonization. Cochrane Database Syst Rev 2014; CD007467.
12. Royal College of Obstetricians and Gynaecologists. The prevention of early onset 
neonatal group B streptococcal disease. London: RCOG, 2012.
13. Nederlandse Vereniging voor Obstetrie en Gynaecologie. Preventie van neona-
tale groep B streptokokken [in Dutch]. Amsterdam: Nederlandse Vereniging voor 
Obstetrie en Gynaecologie, 2008.
14. Royal College of Obstetricians and Gynaecologists. Audit of current practice in 
preventing early-onset neonatal group B streptococcal disease in the UK. London: 
RCOG, 2012.
15. Kolkman DG, Rijnders ME, Wouters MG, et al. Implementation of a cost-effec-
tive strategy to prevent neonatal early-onset group B haemolytic Streptococcus 
disease in the Netherlands. BMC Pregnancy Childbirth 2013; 13:155.
16. Lawn JE, Bianchi-Jassir F, Russell 1, et al. Group B streptococcal disease world-
wide for pregnant women, stillbirths, and children: why, what and how to under-
take estimates? Clin Infect Dis 2017; 65(suppl 2):S89–100.
17. Russell N, Seale AC, O’Driscoll M, et  al. Maternal colonization with group 
B Streptococcus and serotype distribution worldwide: systematic review and 
meta-analyses. Clin Infect Dis 2017; 65(suppl 2):S100–11.
18. Hall J, Hack Adams N, Bartlett L, et al. Maternal disease with group B Streptococcus 
and serotype distribution worldwide: systematic review and meta-analyses. Clin 
Infect Dis 2017; 65(suppl 2):S112–24.
19. Seale AC, Blencowe H, Bianchi-Jassir F, et al. Stillbirth with group B streptococcal 
disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017; 
65(suppl 2):S125–32.
20. Bianchi-Jassir F, Seale AC, Kohli-Lynch M, et al. Preterm birth associated with 
group B Streptococcus maternal colonization worldwide: systematic review and 
meta-analyses. Clin Infect Dis 2017; 65(suppl 2):S133–42.
21. Tann CJ, Martinello K, Sadoo S, et  al. Neonatal encephalopathy with group B 
streptococcal disease worldwide: systematic review, investigator group datasets, 
and meta-analysis. Clin Infect Dis 2017; 65(suppl 2):S173–89.
Downloaded from https://academic.oup.com/cid/article-abstract/65/suppl_2/S143/4589585
by St George's University of London user
on 10 November 2017
Intrapartum Antibiotic Chemoprophylaxis for GBS • CID 2017:65 (Suppl 2) • S151
22. Kohli-Lynch M, Russell N, Seale AC, et al. Neurodevelopmental impairment in 
children after group B streptococcal disease worldwide: systematic review and 
meta-analyses. Clin Infect Dis 2017; 65(suppl 2):S190–9.
23. Seale AC, Bianchi-Jassir F, Russell N, et al. Estimates of the burden of group B 
streptococcal disease worldwide for pregnant women, stillbirths, and children. 
Clin Infect Dis 2017; 65(suppl 2):S200–19.
24. Liberati A, Altman DG, Tetzlaff J, et  al. The PRISMA statement for reporting 
systematic reviews and meta-analyses of studies that evaluate health care inter-
ventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
25. Stevens GA, Alkema L, Black RE, et  al; GATHER Working Group. Guidelines 
for accurate and transparent health estimates reporting: the GATHER statement. 
PLoS Med 2016; 13:e1002056.
26. International Federation of Gynecology and Obstetrics. Our members. Available 
at: http://www.figo.org/our-members. Accessed 25 January 2017.
27. World Health Organization. WHO recommendations for prevention and treat-
ment of maternal peripartum infections. Geneva, Switzerland: WHO, 2015.
28. Ledger WJ, Blaser MJ. Are we using too many antibiotics during pregnancy? 
BJOG 2013; 120:1450–2.
29. Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. Changing patterns in 
neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum 
antibiotic prophylaxis. Pediatrics 2008; 121:689–96.
30. Schrag SJ, Hadler JL, Arnold KE, Martell-Cleary P, Reingold A, Schuchat A. Risk 
factors for invasive, early-onset Escherichia coli infections in the era of widespread 
intrapartum antibiotic use. Pediatrics 2006; 118:570–6.
31. Schrag SJ, Farley MM, Petit S, et al. Epidemiology of invasive early-onset neonatal 
sepsis, 2005 to 2014. Pediatrics 2016; 138.
32. Mulla ZD, Ebrahim MS, Gonzalez JL. Anaphylaxis in the obstetric patient: analy-
sis of a statewide hospital discharge database. Ann Allergy Asthma Immunol 2010; 
104:55–9.
33. Cacho N, Neu J. Manipulation of the intestinal microbiome in newborn infants. 
Adv Nutr 2014; 5:114–8.
34. Castanys-Muñoz E, Martin MJ, Vazquez E. Building a beneficial microbiome 
from birth. Adv Nutr 2016; 7:323–30.
35. Kim SY, Russell LB, Park J, et al. Cost-effectiveness of a potential group B strep-
tococcal vaccine program for pregnant women in South Africa. Vaccine 2014; 
32:1954–63.
Downloaded from https://academic.oup.com/cid/article-abstract/65/suppl_2/S143/4589585
by St George's University of London user
on 10 November 2017
